Biocon Limited
Clinical trials sponsored by Biocon Limited, explained in plain language.
Biopharmaceutical company producing biosimilars and novel biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug shows promise in controlling transplant complications
Disease control CompletedThis study tested a new drug called EQ001 in 30 people who developed acute graft-versus-host disease (aGVHD) after a stem cell transplant. aGVHD is a serious condition where donor immune cells attack the patient's body. The goal was to see if EQ001 is safe and can help control th…
Phase: PHASE1, PHASE2 • Sponsor: Biocon Limited • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New lupus drug shows promise in early safety trial
Disease control CompletedThis early-stage trial tested a drug called itolizumab (EQ001) in 52 adults with lupus, some of whom also had active kidney inflammation. The main goal was to check safety and find the right dose. Researchers also looked at how the drug behaves in the body and how it affects immu…
Phase: PHASE1 • Sponsor: Biocon Limited • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New asthma drug shows promise in early safety trial
Disease control CompletedThis early-stage trial tested a drug called itolizumab (EQ001) in 18 adults with moderate-to-severe asthma that is not well controlled by standard treatments. The main goal was to see if the drug is safe and how the body processes it. Researchers also looked for early signs that …
Phase: PHASE1 • Sponsor: Biocon Limited • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC